The FDA has approved the Abbreviated New Drug Application (ANDA) number ANDA089615 for an inhalation solution containing ISOETHARINE HYDROCHLORIDE.
The product, marketed by AstraZeneca, is identified as ISOETHARINE HYDROCHLORIDE, dosage form solution, route inhalation, strength 0.125%, product number 001, and is not a reference drug or reference standard. Its marketing status is listed as discontinued.
Submission history shows an original submission approved on June 13, 1991, and a supplemental labeling submission approved on November 16, 1992.
Regulatory UpdatesSep 25, 2026•1 min read
FDA Approves AstraZeneca ISOETHARINE Inhalation (ANDA089615)
The FDA approved ANDA089615 for ISOETHARINE HYDROCHLORIDE inhalation solution (0.125%) by AstraZeneca. The product is listed as discontinued.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating